- Elumina is a Phase 2, multicenter, double-blind, randomized, placebo-controlled, clinical trial to assess the efficacy, ...
Algernon Pharmaceuticals Inc. (the "Company" or "AGN Pharma") , a Canadian clinical stage pharmaceutical development company, is pleased to announce that its wholly owned subsidiary Algernon ...
Presented positive interim data through 52 weeks and beyond for 4D-150 in wet AMD from PRISM Phase 1/2 clinical trial highlighting robust and ...
today reported full year 2024 financial results, provided operational highlights and outlined expected upcoming milestones. “2024 was a landmark year for 4DMT, driven by groundbreaking clinical ...
Copyright © 2025 BBC. The BBC is not responsible for the content of external sites. Read about our approach to external linking.
Please Note: All times UK. Tables are subject to change. The BBC is not responsible for any changes that may be made. National League N / S All competitions All competitions All competitions ...
Presented positive interim data through 52 weeks and beyond for 4D-150 in wet AMD from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse patient populatio ...
Hosted on MSN21d
Bumper results day sees RIO, FMG, PLS and more reportbeat consensus estimates with its full-year payout, delivering 60% of 2024 profits to shareholders in the form of a $4.02 full year dividend. That saw returns fall 8% to US$6.5bn ($10.24bn) as ...
Algernon Pharmaceuticals Inc., a Canadian clinical stage pharmaceutical development company, announced that its wholly owned subsidiary, Algernon NeuroScience (AGN Neuro), has appointed Dr. Sándor ...
Loop Industries ( NASDAQ:LOOP ) Full Year 2024 Results Key Financial Results Net loss ... GLOBAL COMMERCIAL ROLLOUT OF THE INFINITE LOOP™ TECHNOLOGY LOOP AND REED TO FORM JOINT VENTURE TO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback